Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Sales Sag 9.3% in April-September on COVID-19, Price Cuts
November 2, 2020
- Daiichi Sankyo’s 6-Month Operating Profit Falls 32% on Higher SGA Costs for Enhertu, ADC R&D Spending
November 2, 2020
- Astellas Earnings Flounder in April-September on LOEs, Deal Terminations
November 2, 2020
- European Regulators Accept Aducanumab for Review: Biogen/Eisai
November 2, 2020
- Ex-Merck Serono President Leo Lee Becomes Japan Chief of Novartis
November 2, 2020
- Lilly Pairs Up with Daiichi Sankyo to Commercialize Migraine Med Galcanezumab in Japan
November 2, 2020
- Daiichi Sankyo to Buyback 60 Million of Own Shares, Canceling 180 Million Treasury Shares
November 2, 2020
- Astellas Completes US iota Buyout to Shore Up Development of Implantable Medical Devices
November 2, 2020
- Takeda Done with Majority of Non-Core Asset Divestitures with US$10 Billion Target Achieved: CEO
October 30, 2020
- Takeda’s Half-Year Operating Profit Nearly Doubles on Drop in Costs, Shire Synergies
October 30, 2020
- Emerging from Repeated Price Cuts, Opdivo’s Japan Sales Could Top 100 Billion Yen in FY2020
October 30, 2020
- Ono’s Half-Year Operating Profit Up 25.1% on Double-Digit Drop in R&D, SGA Costs Amid COVID-19
October 30, 2020
- GSK Might Adjust Shipments for Cervarix as Surge in Demand Expected
October 29, 2020
- Sumitomo Dainippon’s Japan Sales Activities Hit by COVID-19, Virtual Calls Strengthened: President
October 29, 2020
- Sumitomo Dainippon’s Half-Year Sales Up 13.4% on Latuda Growth
October 29, 2020
- Santen Gets Asian Rights to Aerie’s Glaucoma Meds
October 29, 2020
- Enhertu Earns FDA’s Priority Tag for Gastric Cancer, Decision Due in Q1 2021
October 29, 2020
- AbbVie’s JAK Inhibitor Rinvoq Filed for Atopic Dermatitis in Japan
October 29, 2020
- Eisai Launches JV in China to Forge Health Service Platform for Elderly
October 29, 2020
- Copay Rose for Some Patients as Leuplin Issue Triggered Shortage of 6-Month Depot: HCPs
October 28, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…